Innovative MedTech, Inc. Reports Q3 2025 Loss and Strategic Shift Amidst Financial Challenges

Innovative MedTech, Inc. (PINK: IMTH) - Q3 2025 Update

Innovative MedTech, Inc. continues to navigate significant challenges while pursuing expansion in the healthcare technology sector. The company's recent quarterly financial reports reveal both troubling deficits and ambitious plans for innovation and partnerships.

Key Highlights:

• Revenue (Q3 2025): $0; consistent with Q3 2024.
• Operating Expenses: $56,659 in Q3 2025, a 93.45% decrease from $865,194 in Q3 2024 due to reduced consulting fees and administrative costs.
• Net Loss (Q3 2025): $117,510, down from $865,105 in Q3 2024.
• Accumulated Deficit: $46,657,824 as of March 31, 2025.
• Current Assets: $250,386, with available cash dwindling to $351.
• Current Liabilities: $4,015,719, includes significant accrued interests and notes payable.

Positive Aspects:

• Drastic reduction in operating expenses points to better cost management strategies.
• Engagements in innovative partnerships aimed at increasing market footprint in medical technology.

Negative Aspects:

• No revenue generated from core operations, attributable to the transition strategy of divesting from the adult daycare services.
• Significant current liabilities raise concern about future cash flows and liquidity.
• Ongoing defaults on several convertible notes, which might impact investor confidence and financial stability.

Looking ahead, Innovative MedTech, Inc. plans to intensify efforts to raise capital through potential loans and offerings while maintaining focus on its strategy to innovate within healthcare technology. However, uncertainties regarding its liquidity and operational cash flow remain critical points for potential investors.